Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

被引：0

作者：

Lu, Jing ^{[1
]}

Wang, Ying ^{[2
]}

Qiu, Huiying ^{[3
]}

Zhou, Xin ^{[4
]}

Lu, Xuzhang ^{[5
]}

Miao, Miao ^{[6
]}

Gu, Bin ^{[1
]}

Hu, Xiaohui ^{[1
]}

Wu, Depei ^{[6
]}

Chen, Suning ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis,Dept Hematol, Suzhou, Peoples R China

[2] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Suzhou, Peoples R China

[3] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol,Natl Clin Res Ctr Hematol Di, Dept Hematol,Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

[4] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, Wuxi, Jiangsu, Peoples R China

[5] Nanjing Med Univ, Affiliated Changzhou Hosp 2, Dept Hematol, Changzhou, Jiangsu, Peoples R China

[6] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174831

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study
Topp, M. S.
Goekbuget, N.
Stein, A. S.
Bargou, R. C.
Dombret, H.
Fielding, A. K.
Ribera, J. M.
Foa, R.
Zugmaier, G.
Jia, C.
Maniar, T.
Huber, B.
Nagorsen, D.
Kantarjian, H. M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 181 - 181
[32] Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
Xiaohui Suo
Fang Zheng
Dongmei Wang
Liyun Zhao
Jie Liu
Ling Li
Zhihua Zhang
Congcong Zhang
Yinling Li
Sisi Yang
Xuemei Zhao
Rui Shi
Yan Wu
Zongjiu Jiao
Jiaojie Song
Ling Zhang
Xinxiao Lu
Linyu Yuan
Sifeng Gao
Jilei Zhang
Xingli Zhao
Guanchen Bai
Kaiqi Liu
Yingchang Mi
Experimental Hematology & Oncology, 12
[33] Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan
Koh, Katsuyoshi
Kato, Motohiro
Saito, Akiko M.
Kada, Akiko
Kawasaki, Hirohide
Okamoto, Yasuhiro
Imamura, Toshihiko
Horibe, Keizo
Manabe, Atsushi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (07) : 684 - 691
[34] Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study
Gong, Xiaoyuan
Fang, Qiuyun
Gu, Runxia
Qiu, Shaowei
Liu, Kaiqi
Lin, Dong
Zhou, Chunlin
Zhang, Guangji
Gong, Benfa
Liu, Yuntao
Wei, Shuning
Li, Yan
Li, Shouyun
Liu, Bingcheng
Hu, Yimin
Li, Junfan
Wang, Ying
Wei, Hui
Mi, Yingchang
Wang, Jianxiang
BLOOD, 2023, 142
[35] Interim results of a multicenter, single-arm study to assess Blinatumomab in adult patients (pts) with minimal residual disease (MRD) of B-precursor (BCP) acute lymphoblastic leukemia (GMALL-MOLACT1-BLINA)
Wermann, W. K.
Schwartz, S.
Fiedler, W.
Kayser, S.
Huettmann, A.
Alakel, N.
Bargou, R.
Faul, C.
Heidenreich, D.
Jung, W.
Martin, S.
Subklewe, M.
Topp, M.
Viardot, A.
Vucinic, V.
Waesch, R.
Brueggemann, M.
Goekbuget, N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 174 - 175
[36] Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)
Goekbuget, Nicola
Wermann, Wiba Keke
Schwartz, Stefan
Huttmann, Andreas
Faul, Christoph
Raffel, Simon
Viardot, Andreas
Fiedler, Walter
Alakel, Nael
Stelljes, Matthias
Subklewe, Marion
Wasch, Ralph
Martin, Sonja
Jung, Wolfram
Vucinic, Vladan
Kondakci, Mustafa
Fransecky, Lars R.
Heidenreich, Daniela
Wendelin, Knut
Hermann, Julian
Serve, Hubert
BLOOD, 2020, 136
[37] Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Richard-Carpentier, Guillaume
Kantarjian, Hagop M.
Short, Nicholas J.
Ravandi, Farhad
Ferrajoli, Alessandra
Schroeder, Heather M.
Garcia-Manero, Guillermo
Bravo, Guillermo Montalban
Cortes, Jorge E.
Kwari, Monica
Loiselle, Christopher
Garris, Rebecca
Volter, Nicole
Jain, Nitin
Konopleva, Marina Y.
Takahashi, Koichi
Sasaki, Koji
Wierda, William G.
Jabbour, Elias
BLOOD, 2019, 134
[38] Disease Burden Subgroup Analysis of HealthRelated Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study ( TOWER)
Stein, Anthony S.
Zimmerman, Zachary F.
Cannell, Paul
Dombret, Herve
Maertens, Johan
Topp, Max S.
Franklin, Janet L.
Cong, Ze
Zhang, Xinke
Li, Yan
Schuh, Andre
BLOOD, 2018, 132
[39] Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Nguyen, Daniel
Kantarjian, Hagop M.
Short, Nicholas J.
Jain, Nitin
Haddad, Fadi G.
Yilmaz, Musa
Ferrajoli, Alessandra
Kadia, Tapan M.
Valero, Yesid Alvarado
Maiti, Abhishek
Nasnas, Cedric
Nasr, Lewis
Garris, Rebecca
Konopleva, Marina Y.
Ravandi, Farhad
Jabbour, Elias
BLOOD, 2023, 142
[40] Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Nguyen, Daniel
Kantarjian, Hagop
Short, Nicholas J.
Jain, Nitin
Haddad, Fadi G.
Yilmaz, Musa
Ferrajoli, Alessandra
Kadia, Tapan M.
Valero, Yesid Alvarado
Maiti, Abhishek
Zoghbi, Marianne
Senapati, Jayastu
Garris, Rebecca
Zhao, Min
Konopleva, Marina
Ravandi, Farhad
Jabbour, Elias
BLOOD, 2024, 144 : 1439 - 1441

← 1 2 3 4 5 →